Application of autologous bone marrow mononuclear cells in six patients with advanced chronic critical limb ischemia as a result of diabetes: our experience.

  title={Application of autologous bone marrow mononuclear cells in six patients with advanced chronic critical limb ischemia as a result of diabetes: our experience.},
  author={R Subrammaniyan and Joseph Amalorpavanathan and Rajendran Shankar and M. Rajkumar and Subramani Baskar and Sadananda Rao Manjunath and Rajappa Senthilkumar and Palanisamy Murugan and V Srinivasan and Samuel J. K. Abraham},
  volume={13 8},
BACKGROUND AIMS Previous clinical studies have reported that the injection of bone marrow (BM)-derived mononuclear cells (MNC) results in improvement in symptoms and healing of ulcers in patients with critical limb ischemia (CLI) up to stage IV of Fontaine's classification. However, most patients with Fontaine stage IV CLI limbs had to undergo amputation even after stem cell therapy. We report on six patients, who had poorly controlled diabetes with extensive ulceration and gangrene of limbs… 

Autologous bone marrow stem cell transplantation for the treatment of postoperative hand infection with a skin defect in diabetes mellitus: A case report

Transplantation of autologous MSCs may play a role in the clinical application of stem cells, particularly for treatment of skin defects following surgery in cases of DM and for those caused by various other traumas.

Autologous Bone-Marrow vs. Peripheral Blood Mononuclear Cells Therapy for Peripheral Artery Disease in Diabetic Patients

The present literature review will focus on comparing safety and efficacy between BMMNC and PBMNC as cell-based management in diabetic patients with PAD who are not suitable for revascularization therapy.

Combining Autologous Peripheral Blood Mononuclear Cells with Fibroblast Growth Factor Therapy Along with Stringent Infection Control Leading to Successful Limb Salvage in Diabetic Patient with Chronic Renal Failure and Severe Toe Gangrene

A 38 year old male who reported with DM, chronic kidney disease (CKD) and rest pain of the right second toe in October 2011, underwent percutaneous transluminal angioplasty (PTA) which was unsuccessful and amputation of theRight third toe was performed and the fourth toe was amputated.

Autologous bone marrow cell therapy for peripheral arterial disease

The authors believe that additional research initiatives should be undertaken to better identify the nature of stem cells and that an intensive cooperation between laboratory and clinical investigators is needed to optimize the design of cell therapy trials and to maximize their scientific rigor.

Cancer risk is not increased in patients treated for orthopaedic diseases with autologous bone marrow cell concentrate.

This study found no increased cancer risk in patients after application of autologous cell-based therapy using bone marrow-derived stromal progenitor cells either at the treatment site or elsewhere in the patients after an average follow-up period of 12.5 years.

Stem and Somatic Cell Monotherapy for the Treatment of Diabetic Foot Ulcers: Review of Clinical Studies and Mechanisms of Action.

Undoubtedly, cell therapy is a potent tool for the treatment of DFU, however, it is vital to conduct further high-quality clinical research to determine the most effective cell type, dosage and way of administration for DFU treatment.

Safety and Efficacy of Autologous Cell Therapy in Critical Limb Ischemia: A Systematic Review

Cell therapy presents a favorable safety profile with a low adverse event rate and no increase in severe events such as mortality and cancer and treatment with cell therapy decreases the risk of amputation, and has a positive benefit-to-risk ratio in CLI.

Application of adipose-derived stem cells in critical limb ischemia.

Adipose-derived stem cells (ASCs) have significant potential for tissue repair under conditions of myocardial infarction, heart failure, hind limb ischemia, and inflammation, and this review highlights some of the key reports underlining the potential of ASCs, particularly in diseases involving neovascularization.

Multipotent bone marrow stromal cell therapy promotes endogenous cell proliferation following ischemic stroke

The understanding of the effects of bone marrow stromal cell (BMSC) treatment following experimentally induced ischemic stroke in rats is extended and the therapeutic potential of BMSCs as an effective treatment following cerebral stroke is argued for.

Bone marrow derived stem cell therapy for type 2 diabetes mellitus.

Five of 6 patients with type 2 diabetes underwent autologous bone marrow mononuclear stem cell infusion into the celiac and superior mesenteric arteries without pretreatment with any myeloablative or immune-suppressive therapy and showed normalization of their fasting glucose and the glycosylated hemoglobin.



Autologous intra-arterial infusion of bone marrow mononuclear cells in patients with critical leg ischemia.

Intra-arterial infusion of BMMC can lead to significant and long-lasting subjective and objective improvements in patients with CLI, and merit validation by randomized controlled studies in Patients with less critical limb ischemia.

Treatment with Autologous Bone Marrow Mononuclear Cells in Patients with Critical Lower Limb Ischaemia. A Pilot Study

  • T. WesterJ. Jørgensen J. Brinchmann
  • Medicine
    Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society
  • 2008
While symptomatic improvement was found in individual patients, larger trials are required to investigate efficacy, and this method seems to be a safe option for treating patients with CLI.

Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia.

Transplantation of autologous bone marrow mononuclear cells is a simple, safe and effective method for the treatment of lower limb ischemia, and the two approaches for the implantation, intra-muscular injection and intra-arterial injection, show similar results.

[Transplantation of autologous adult bone marrow stem cells in patients with severe peripheral arterial occlusion disease].

It is demonstrated, that the combined intraarterial and intramuscular transplantation of autologous adult bone marrow stem cells leads to a significant improvement of perfusion indices in patients with severe PAOD.

The treatment of advanced chronic lower limb ischaemia with marrow stem cell autotransplantation.

Marrow stem cell autotransplantation into the ischaemic lower limb seems to be a potentially effective method of peripheral perfusion enhancement.

[Autologous bone-marrow stem-cell transplantation for induction of arteriogenesis for limb salvage in critical limb ischaemia].

In no-option patients with end-stage critical limb ischaemia due to peripheral -artery disease, bone marrow cell transplantation is a safe procedure which can improve leg perfusion sufficiently to reduce major amputations and permit durable limb salvage.

Prevention of Limb Amputation in Patients with Limbs Ulcers by Autologous Peripheral Blood Mononuclear Cell Implantation

  • A. KawamuraT. Horie M. Kasai
  • Medicine, Biology
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  • 2005
This is the first large report of the application of regenerative medicine to peripheral ischemic limbs by autologous peripheral blood stem cell (PBSC) implantation where imminent amputation was under consideration.

Autologous Bone Marrow Cell Transplantation Increases Leg Perfusion and Reduces Amputations in Patients with Advanced Critical Limb Ischemia Due to Peripheral Artery Disease

In no-option patients with end-stage critical limb ischemia due to peripheral artery disease, bone marrow cell transplantation is a safe procedure that can improve leg perfusion sufficiently to reduce major amputations and permit durable limb salvage.

Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia.

The TACT regimen improved CLI in patients with Buerger's disease but not in those with ASO-HD in this small study.